R Heijtink

Summary

Affiliation: Erasmus University
Country: The Netherlands

Publications

  1. ncbi Characteristics of the early phase of chronicity in acute hepatitis B infection
    R A Heijtink
    Department of Virology, Erasmus University Rotterdam, The Netherlands
    J Med Virol 57:331-6. 1999
  2. ncbi Anti-HBs levels after hepatitis B immunisation depend on test reagents: routinely determined 10 and 100 IU/l seroprotection levels unreliable
    R A Heijtink
    Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands
    Vaccine 20:2899-905. 2002
  3. ncbi Hepatitis B surface antigen (HBsAg) derived from yeast cells (Hansenula polymorpha) used to establish an influence of antigenic subtype (adw2, adr, ayw3) in measuring the immune response after vaccination
    R A Heijtink
    Department of Virology, Erasmus Medical Centre Rotterdam, Rotterdam, The Netherlands
    Vaccine 20:2191-6. 2002
  4. ncbi Characterization of a human monoclonal antibody obtained after immunization with plasma vaccine and a booster with recombinant-DNA hepatitis B vaccine
    R A Heijtink
    Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands
    J Med Virol 66:304-11. 2002
  5. ncbi Administration of a human monoclonal antibody (TUVIRUMAB) to chronic hepatitis B patients pre-treated with lamivudine: monitoring of serum TUVIRUMAB in immune complexes
    R A Heijtink
    Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands
    J Med Virol 64:427-34. 2001
  6. ncbi Anti-HBs after hepatitis B immunization with plasma-derived and recombinant DNA-derived vaccines: binding to mutant HBsAg
    R A Heijtink
    Department of Virology, Erasmus University Rotterdam, PO Box 1738, 3000 DR Rotterdam, Netherlands
    Vaccine 19:3671-80. 2001
  7. ncbi Interferon-alpha therapy for chronic hepatitis B: early response related to pre-treatment changes in viral replication
    R A Heijtink
    Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands
    J Med Virol 63:217-9. 2001
  8. ncbi Anti-HBs characteristics after hepatitis B immunisation with plasma-derived and recombinant DNA-derived vaccines
    R A Heijtink
    Department of Virology, Erasmus Medical Centre Rotterdam, Rotterdam, P O Box 1738, 3000 DR, Rotterdam, Netherlands
    Vaccine 18:1531-8. 2000
  9. ncbi In vivo activity of a mixture of two human monoclonal antibodies (anti-HBs) in a chronic hepatitis B virus carrier chimpanzee
    R Heijtink
    Department of Virology, Erasmus University Rotterdam, The Netherlands
    J Gen Virol 80:1529-35. 1999
  10. ncbi Passive immunization of chronic hepatitis B patients on lamivudine therapy: a feasible issue?
    A B van Nunen
    Department of Hepatology and Gastroenterology, Erasmus Medical Center Rotterdam, The Netherlands
    J Viral Hepat 9:221-8. 2002

Collaborators

Detail Information

Publications11

  1. ncbi Characteristics of the early phase of chronicity in acute hepatitis B infection
    R A Heijtink
    Department of Virology, Erasmus University Rotterdam, The Netherlands
    J Med Virol 57:331-6. 1999
    ..Differentiation of the antibody response to HBeAg may help to find patients with an increased risk for this interrupted immune clearance who might be candidates for an early intervention therapy...
  2. ncbi Anti-HBs levels after hepatitis B immunisation depend on test reagents: routinely determined 10 and 100 IU/l seroprotection levels unreliable
    R A Heijtink
    Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands
    Vaccine 20:2899-905. 2002
    ..We conclude that the individually determined anti-HBs level (IU/l) strongly depend on the test reagents and the vaccine under study...
  3. ncbi Hepatitis B surface antigen (HBsAg) derived from yeast cells (Hansenula polymorpha) used to establish an influence of antigenic subtype (adw2, adr, ayw3) in measuring the immune response after vaccination
    R A Heijtink
    Department of Virology, Erasmus Medical Centre Rotterdam, Rotterdam, The Netherlands
    Vaccine 20:2191-6. 2002
    ....
  4. ncbi Characterization of a human monoclonal antibody obtained after immunization with plasma vaccine and a booster with recombinant-DNA hepatitis B vaccine
    R A Heijtink
    Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands
    J Med Virol 66:304-11. 2002
    ..The characterisation of 1Ff4 and other human monoclonal anti-HBs antibodies may help to understand the fine specificity of protective antibodies elicited by immunization...
  5. ncbi Administration of a human monoclonal antibody (TUVIRUMAB) to chronic hepatitis B patients pre-treated with lamivudine: monitoring of serum TUVIRUMAB in immune complexes
    R A Heijtink
    Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands
    J Med Virol 64:427-34. 2001
    ....
  6. ncbi Anti-HBs after hepatitis B immunization with plasma-derived and recombinant DNA-derived vaccines: binding to mutant HBsAg
    R A Heijtink
    Department of Virology, Erasmus University Rotterdam, PO Box 1738, 3000 DR Rotterdam, Netherlands
    Vaccine 19:3671-80. 2001
    ..The presented differentiation in anti-HBs response after immunization may deliver new tools for evaluation of future vaccines...
  7. ncbi Interferon-alpha therapy for chronic hepatitis B: early response related to pre-treatment changes in viral replication
    R A Heijtink
    Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands
    J Med Virol 63:217-9. 2001
    ..Planning the start of interferon treatment just after a spontaneous decrease in HBV replication may increase the response rate for interferon-alpha therapy...
  8. ncbi Anti-HBs characteristics after hepatitis B immunisation with plasma-derived and recombinant DNA-derived vaccines
    R A Heijtink
    Department of Virology, Erasmus Medical Centre Rotterdam, Rotterdam, P O Box 1738, 3000 DR, Rotterdam, Netherlands
    Vaccine 18:1531-8. 2000
    ..It is suggested that a challenge with an heterologous hepatitis B virus may encounter reduced efficacy of vaccine antibodies...
  9. ncbi In vivo activity of a mixture of two human monoclonal antibodies (anti-HBs) in a chronic hepatitis B virus carrier chimpanzee
    R Heijtink
    Department of Virology, Erasmus University Rotterdam, The Netherlands
    J Gen Virol 80:1529-35. 1999
    ..Monoclonals 9H9 and 4-7B may complement each other due to their different mechanisms of inactivation, probably with higher efficiency than that monitored by our HBsAg screening assays...
  10. ncbi Passive immunization of chronic hepatitis B patients on lamivudine therapy: a feasible issue?
    A B van Nunen
    Department of Hepatology and Gastroenterology, Erasmus Medical Center Rotterdam, The Netherlands
    J Viral Hepat 9:221-8. 2002
    ..Passive immunization in HBV-DNA negative patients is not a feasible option. This strategy seems only feasible if agents inhibiting both the production of viral proteins and Dane particles more selectively, become available...
  11. ncbi Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBe-antigen positive hepatitis B patients treated with interferon-alpha
    A A van der Eijk
    Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, The Netherlands
    J Viral Hepat 13:96-103. 2006
    ....